The family of the interleukin-1 receptors

Immunological Reviews

Volumn 281, Issue 1, 2018, Pages 197-232

  Boraschi, Diana ^a   Italiani, Paola ^a   Weil, Sabrina ^b   Martin, Michael U ^b  

^a INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

IL 1 receptors; IL 1R family; Inflammation; Interleukin 1; Resolution

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 10; INTERLEUKIN 1 RECEPTOR 3; INTERLEUKIN 1 RECEPTOR 4; INTERLEUKIN 1 RECEPTOR 5; INTERLEUKIN 1 RECEPTOR 6; INTERLEUKIN 1 RECEPTOR 7; INTERLEUKIN 1 RECEPTOR 8; INTERLEUKIN 1 RECEPTOR 9; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-18; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 85038030881     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12606     Document Type: Review

References (461)

1. Aarden L, Brunner TK, Cerottini J-C, et al. Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol. 1979;123:2928-2929.
2. Lomedico PT, Gubler U, Hellmann CP, et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature. 1984;312:458-462.
3. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature. 1985;315:641-647.
4. Auron PE, Webb AC, Rosenwasser LJ, et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA. 1984;81:7907-7911.
5. Dower SK, Kronheim SR, March CJ, et al. Detection and characterization of high affinity plasma membrane receptors for human interleukin 1. J Exp Med. 1985;162:501-515.
6. Dower SK, Kronheim SR, Hopp TP, et al. The cell surface receptors for interleukin-1 alpha and interleukin-1beta are identical. Nature. 1986;324:266-268.
7. Sims JE, March CJ, Cosman D, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science. 1988;241:585-589.
8. Sims JE, Acres RB, Grubin CE, et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci USA. 1989;86:8946-8950.
9. Curtis BM, Gallis B, Overell RW, et al. T-cell interleukin 1 receptor cDNA expressed in Chinese hamster ovary cells regulates functional responses to interleukin 1. Proc Natl Acad Sci USA. 1989;86:3045-3049.
10. Dower SK, Qwarnstrom EE, Page RC, et al. Biology of the interleukin-1 receptor. J Invest Dermatol. 1990;94:68S-73S.
11. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem. 1995;270:13757-13765.
12. Wesche H, Korherr C, Kracht M, Falk W, Resch K, Martin MU. The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J Biol Chem. 1997;272:7727-7731.
13. Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997;27:262-267.
14. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature. 1991;351:355-356.
15. Heguy A, Baldari CT, Macchia G, Telford JL, Melli M. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila toll protein are essential for IL-1R signal transduction. J Biol Chem. 1992;267:2605-2609.
16. Anderson KV, Jürgens G, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: Genetic studies on the role of the Toll gene product. Cell. 1985;42:779-789.
17. Anderson KV, Bokla L, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: The induction of polarity by the Toll gene product. Cell. 1985;42:791-798.
18. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973-983.
19. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397.
20. Poltorak A, Smirnova I, He X, et al. Genetic and physical mapping of the Lps locus: Identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis. 1998;24:340-355.
21. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science. 1998;282:2085-2088.
22. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998;95:588-593.
23. Schneider DS, Hudson KL, Lin TY, Anderson KV. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo. Genes Dev. 1991;5:797-807.
24. Hultmark D. Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. Biochem Biophys Res Commun. 1994;199:144-146.
25. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997;278:1612-1615.
26. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997;7:837-847.
27. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998;2:253-258.
28. Parker JE, Coleman MJ, Szabò V, et al. The Arabidopsis downy mildew resistance gene RPPS shares similarity to the Toll and Interleukin-1 receptors with N and L6. Plant Cell. 1997;9:879-894.
29. Meyers BC, Dickerman AW, Michelmore RW, Sivaramakrishnan S, Sobral BW, Young ND. Plant disease resistance genes encode members of an ancient and diverse protein family within the nucleotide-binding superfamily. Plant J. 1999;20:317-332.
30. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Semin Immunol. 2013;25:394-407.
31. Boraschi D. IL-1 receptor family. In: Encyclopedia of Signaling Molecules, 2nd edn. New York: Springer Science amp; Business Media LLC; 2017; in press. ISBN: 978-3-319-67198-7.
32. Dinarello CA. Overview of the interleukin 1 family of cytokines and receptors. Sem Immunol. 2013;25:389-393.
33. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: Back to the future. Immunity. 2013;39:1003-1018.
34. Boraschi D. IL-1 family. In: Choi S, ed. Encyclopedia of Signaling Molecules, 2nd edn. New York: Springer Science & Business Media LLC; 2017; in press. ISBN: 978-3-319-67198-7.
35. Buckley KM, Rast JP. Dynamic evolution of toll-like receptor multigene families in echinoderms. Front Immunol. 2012;3:136.
36. Satake H, Sekiguchi T. Toll-like receptors of deuterostome invertebrates. Front Immunol. 2012;3:34.
37. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991;10:2821-2832.
38. Ogata H, Su I, Miyake K, et al. The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells. J Exp Med. 2000;192:23-29.
39. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: The Toll-like receptors and their transducers. J Leukoc Biol. 2003;74:479-485.
40. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558-561.
41. Kirschning CJ, Schumann RR. TLR2: Cellular sensor for microbial and endogenous molecular patterns. Curr Top Microbiol Immunol. 2002;270:121-144.
42. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: An integrated view. Immunol Rev. 2011;2431:136-151.
43. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleukin-33 – Cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227-233.
44. Rider P, Voronov E, Dinarello CA, Apte RN, Cohen I. Alarmins: Feel the stress. J Immunol. 2017;198:1395-1402.
45. Martin SJ. Cell death and inflammation: The case for IL-1 family cytokines as the canonical DAMPs of the immune system. FEBS J. 2016;283:2599-2615.
46. Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016;17:122-131.
47. Lin H, Ho AS, Haley-Vicente D, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem. 2001;276:20597-20602.
48. Mora J, Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8:426-438.
49. Svenson M, Hansen MB, Heegaard P, Abell K, Bendzen K. Specific binding of interleukin 1 (IL-1) β and IL-1 receptor antagonist (IL-1ra) to human serum. High affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine. 1993;5:427-435.
50. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995;96:38-41.
51. Spriggs MK, Lioubin PJ, Slack J, et al. Induction of an interleukin-1 receptor (IL-1R) on monocytic cells: Evidence that the receptor is not encoded by a T cell-type IL-1R mRNA. J Biol Chem. 1990;265:22499-22505.
52. Penton-Rol G, Orlando S, Polentarutti N, et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol. 1999;162:2931-2938.
53. Colotta F, Dower SK, Sims JE, Mantovani A. The type II ‘decoy’ receptor: A novel regulatory pathway for interleukin 1. Immunol Today. 1994;15:562-566.
54. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA. 1995;92:1714-1718.
55. Klemenz R, Hoffmann S, Werenskiold AK. Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA. 1989;86:5708-5712.
56. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
57. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett. 1993;318:83-87.
58. Trajkovic V, Sweet MJ, Xu D. T1/ST2 – An IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15: 87-95.
59. Gayle MA, Slack JL, Bonnert TP, et al. Cloning of a putative ligand for the T1/ST2 receptor. J Biol Chem. 1996;271:5784-5789.
60. Dunn E, Sims JE, Nicklin MJ, O’Neill LA. Annotating genes with potential roles in the immune system: Six new members of the IL-1 family. Trends Immunol. 2001;22:533-536.
61. Li H, Tago K, Io K, et al. The cloning and nucleotide sequence of human ST2L cDNA. Genomics. 2000;67:284-290.
62. Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285:1377-1383.
63. Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors – Insight into heterotrimeric IL-1 signaling complexes. Structure. 2009;17:1398-1410.
64. Liu X, Hammel M, He Y, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci USA. 2013;110:14918-14923.
65. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem. 1996;271:3967-3970.
66. Torigoe K, Ushio S, Okura T, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997;272:25737-25742.
67. Kumar S, Hanning CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/ IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine. 2002;18:61-71.
68. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA. 2002;99:13723-13728.
69. Lovenberg TW, Crowe PD, Liu C, et al. Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J Neuroimmunol. 1996;70:113-122.
70. Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NF-κB activation through the orphan IL-1 receptor-related protein 2. J Immunol. 2001;167:1440-1446.
71. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-κB and MAPKs. J Biol Chem. 2004;279:13677-13688.
72. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286:42594-42602.
73. van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA. 2012;109:3001-3005.
74. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104:18660-18665.
75. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179:2551-2555.
76. Cullinan EB, Kwee L, Nunes P, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161:5614-5620.
77. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol. 2012;19:455-457.
78. Casadio R, Frigimelica E, Bossù P, et al. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/ IL-1RI complex. FEBS Lett. 2001;499:65-68.
79. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol. 2010;11:905-912.
80. Günther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol. 2014;193:921-930.
81. Jensen LE, Muzio M, Mantovani A, Whitehead AS. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol. 2000;164:5277-5286.
82. Jensen LE, Whitehead AS. Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell Signal. 2003;15:793-802.
83. Järås M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107:16280-16285.
84. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290-1298.
85. Ågerstam H, Karlsson C, Hansen N, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci USA. 2015;112: 10786-10791.
86. Ågerstam H, Hansen N, von Palffy S, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128:2683-2693.
87. Chen R, Li M, Zhang Y, Zhou Q, Shu HAB. The E3 ubiquitin ligase MARCH8 negatively regulates IL-1β-induced NF-κB activation by targeting the IL1RAP coreceptor for ubiquitination and degradation. Proc Natl Acad Sci USA. 2012;109:14128-14133.
88. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem. 1998;273:29445-29450.
89. Takei S, Hoshino T, Matsunaga K, et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R52.
90. Kollewe C, Neumann D, Martin MU. The first two N-terminal immunoglobulin-like domains of soluble human IL-1 receptor type II are sufficient to bind and neutralize IL-1β. FEBS Lett. 2000;29:189-193.
91. Neumann D, Kollewe C, Martin MU, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol. 2000;165:3350-3357.
92. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science. 1993;261:472-475.
93. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine. 1999;11:389-399.
94. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits Interleukin-1 receptor-and Toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem. 2005;280:25233-25241.
95. Garlanda C, Riva F, Bonavita E, Gentile S, Mantovani A. Decoys and regulatory “receptors” of the IL-1/ Toll-like receptor superfamily. Frontiers Immunol. 2013;4:180.
96. Polentarutti N, Penton Rol G, Muzio M, et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw. 2003;14:211-218.
97. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signalling. Nat Immunol. 2003;4:920-927.
98. Gu YF, Fang Y, Jin Y, Dong WR, Xiang LX, Shao JZ. Discovery of the DIGIRR gene from teleost fish: A novel Toll-IL-1 receptor family member serving as a negative regulator of IL-1 signaling. J Immunol. 2011;187:2514-2530.
99. Gong J, Wei T, Stark RW, et al. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: A computational approach. J Struct Biol. 2010;169:323-330.
100. Zhao J, Bulek K, Gulen MF, et al. Human colon tumors express a dominant-negative form of SIGIRR that promotes inflammation and colitis-associated colon cancer in mice. Gastroenterology. 2015;149:1860-1868.
101. Vilia MG, Tocchetti M, Fonte E, Sana I, Muzio M. Characterization of a long isoform of IL-1R8 (TIR8/SIGIRR). Eur Cytokine Netw. 2017;28:63-69.
102. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity. 1999;10:127-136.
103. Kim SH, Azam T, Novick D, et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem. 2002;277:10998-11003.
104. Booker CS, Grattan DR. IL1R9 Is Evolutionarily Related to IL18BP and May Function as an IL-18 Receptor. J Immunol. 2017;198:270-278.
105. Harms RZ, Creer AJ, Lorenzo-Arteaga KM, Ostlund KR, Sarvetnick NE. Interleukin (IL)-18 Binding protein deficiency disrupts natural killer cell maturation and diminishes circulating IL-18. Front Immunol. 2017;8:1020.
106. Sana TR, Debets R, Timans JC, Bazan JF, Kastelein RA. Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22. 3. Genomics. 2000;69:252-262.
107. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275:1169-1175.
108. Carrié A, Jun L, Bienvenu T, et al. A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat Genet. 1999;23:25-31.
109. Jin H, Gardner RJ, Viswesvaraiah R, Muntoni F, Roberts RG. Two novel members of the interleukin-1 receptor gene family, one deleted in Xp22.1-Xp21.3 mental retardation. Eur J Hum Genet. 2000;8:87-94.
110. Born TL, Smith DE, Garka KE, Renshaw BR, Bertles JS, Sims JE. Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling. J Biol Chem. 2000;275:29946-29954.
111. Ferrante MI, Ghiani M, Bulfone A, Franco B. IL1RAPL2 maps to Xq22 and is specifically expressed in the central nervous system. Gene. 2001;275:217-221.
112. Gambino F, Pavlowsky A, Béglé A, et al. IL1-receptor accessory protein-like 1 (IL1RAPL1), a protein involved in cognitive functions, regulates N-type Ca2+-channel and neurite elongation. Proc Natl Acad Sci USA. 2007;104:9063-9068.
113. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
114. Dinarello CA. Interleukin-1 in the payhogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
115. Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1α. Sem Immunol. 2013;25:430-438.
116. Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β. Nature. 1997;386:190-194.
117. Schreuder H, Tardif C, Trump-Kallmeyer S, et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 1997;386:194-200.
118. Lang D, Knop J, Wesche H, et al. The type II interleukin-1 receptor interacts with the interleukin-1 receptor accessory protein: A novel mechanism of regulation of the interleukin-1 responsiveness. J Immunol. 1998;161:6871-6877.
119. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990;343:341-346.
120. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1α, interleukin-1β, and interleukin-1 receptor antagonist genes. Genomics. 1994;19:382-384.
121. Vallés S, Tsoi C, Huang W-Y, et al. Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex. Regulation by fibronectin attachment. J Biol Chem. 1999;274(20103):20109.
122. Zhang X, Shephard F, Kim HB, et al. TILRR, a novel IL-1RI co-receptor, potentiates MyD88 recruitment to control Ras-dependent amplification of NF-κB. J Biol Chem. 2010;285:7222-7232.
123. Zhang X, Montagut Pino G, Shephard F, Kiss-Toth E, Qwarnstrom EE. Distinct control of MyD88 adapter-dependent and Akt kinase-regulated responses by the interleukin (IL)-1RI co-receptor, TILRR. J Biol Chem. 2012;287:12348-12352.
124. Rhodes DM, Smith SA, Holcombe M, Qwarnstrom EE. Computational modelling of NF-κB activation by IL-1RI and its co-receptor TILRR, predicts a role for cytoskeletal sequestration of IκBα in inflammatory signalling. PLoS ONE. 2015;10:e0129888.
125. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med. 2014;20:S43-S58.
126. https://www.ncbi.nlm.nih.gov/gene/3554
127. https://www.ncbi.nlm.nih.gov/gene/3556
128. https://www.ncbi.nlm.nih.gov/gene/3556
129. Gresnigt MS, van de Veerdonk FL. Biology of IL-36 cytokines and their role in disease. Sem Immunol. 2013;25:458-465.
130. Touzani O, Boutin H, LeFeuvre R, et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci. 2002;22:38-43.
131. Kuhlow CJ, Krady JK, Basu A, Levison SW. Astrocytic cerluplasmin expression, which is induced by IL-1β and by traumatic brain injury, increases in the absence of the IL-1 type I receptor. Glia. 2003;44:76-84.
132. Loscher CE, Mills KHG, Lynch MA. Interleukin-1 receptor antagonist exerts agonist activity in the hippocampus independent of the interleukin-1 type I receptor. J Neuroimmunol. 2003;137:117-124.
133. Andre R, Moggs JG, Kimber I, Rothwell NJ, Pinteaux E. Gene regulation by IL-1β independent of IL-1R1 in the mouse brain. Glia. 2006;53:477-483.
134. Cebo C, Dambrouck T, Maes E, et al. Recombinant human interleukins IL-1α, IL-1β, IL-4, IL-6, and IL-7 show different and specific calcium-independent carbohydrate-binding properties. J Biol Chem. 2001;276:5685-5691.
135. Vergoten G, Zanetta J-P. Structural differences between the putative carbohydrate recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling. Glycoconj J. 2007;24:183-193.
136. Boraschi D, Nencioni L, Villa L, et al. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human IL-1β. J Exp Med. 1988;168:675-686.
137. Boraschi D, Ghiara P, Scapigliati G, Villa L, Sette A, Tagliabue A. Binding and internalization of the 163-171 fragment of human IL-1β. Cytokine. 1992;4:201-204.
138. Mosley B, Urdal DL, Prickett KS, et al. The interleukin-1 receptor binds the human interleukin-lα precursor but not the interleukin-1β precursor. J Biol Chem. 1987a;262:2941-2944.
139. Mosley B, Dower SK, Gillis S, Cosman D. Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta. Proc Natl Acad Sci USA. 1987b;84:4572-4576.
140. Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell. 2011;44:265-278.
141. Fan J, Cai Y, Huang X, Wang Y, Mu L, Zhou L. Variations in IL-1R1 gene influence risk for Hepatitis B Virus infection of children in a Han Chinese population. Int J Infect Dis. 2017;55:45-50.
142. Liu Y, Liu S, Wu HH, Zhang X. [Association between IL1R1 gene polymorphisms and childhood asthma]. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:243-246.
143. De Marco P, Lappano R, De Francesco EM, et al. GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1β/IL1R1 response. Sci Rep. 2016;6:24354.
144. Pandey GN, Ren X, Rizavi HS, Zhang H. Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res. 2015;164:193-198.
145. Feng B, Tang Y, Chen B, et al. Transient increase of interleukin-1β after prolonged febrile seizures promotes adult epileptogenesis through long-lasting upregulating endocannabinoid signaling. Sci Rep. 2016;6:21931.
146. Machado-Carvalho L, Martín M, Torres R, et al. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/ IL-1 type I receptor/ COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:99-107.
147. Liu Z, Zhang M, Wu J, et al. Serum CD121a (Interleukin 1 Receptor, Type I): A potential novel inflammatory marker for Coronary Heart Disease. PLoS ONE. 2015;10:e0131086.
148. Wu F, He M, Wen Q, et al. Associations between variants in IL-33/ ST2 signaling pathway genes and Coronary Heart Disease risk. Int J Mol Sci. 2014;15:23227-23239.
149. Ramanan VK, Risacher SL, Nho K, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. Brain. 2015;138:3076-3088.
150. Bozaoglu K, Attard C, Kulkarni H, et al. Plasma levels of soluble interleukin 1 receptor accessory protein are reduced in obesity. J Clin Endocrinol Metab. 2014;99:3435-3443.
151. Xia Y, Liu YQ, Chen K, Wang LC, Ma CY, Zhao YR. Association of IL-1R2 genetic polymorphisms with the susceptibility of ankylosing spondylitis in Northern Chinese Han population. Mod Rheumatol. 2015;25:908-912.
152. Momenzadeh P, Mahmoudi M, Beigy M, et al. Determination of IL1 R2, ANTXR2, CARD9, and SNAPC4 single nucleotide polymorphisms in Iranian patients with ankylosing spondylitis. Rheumatol Int. 2016;36:429-435.
153. Langmia IM, Apalasamy YD, Omar SZ, Mohamed Z. Interleukin 1 receptor type 2 gene polymorphism is associated with reduced risk of preterm birth. J Matern Fetal Neonatal Med. 2016;29:3347-3350.
154. Coccaro EF, Lee R, Coussons-Read M. Cerebrospinal fluid inflammatory cytokines and aggression in personality disordered subjects. Int J Neuropsychopharmacol. 2015;18:pyv001.
155. Chen YC, Chen TW, Su MC, et al. Whole genome DNA methylation analysis of obstructive sleep apnea: IL1R2, NPR2, AR, SP140 methylation and clinical phenotype. Sleep. 2016;39:743-755.
156. Kovach MA, Stringer KA, Bunting R, et al. Microarray analysis identifies IL-1 receptor type 2 as a novel candidate biomarker in patients with acute respiratory distress syndrome. Respir Res. 2015;16:29.
157. Niu G, Wang D, Pei Y, Sun L. Systematic identification of key genes and pathways in the development of invasive cervical cancer. Gene. 2017;618:28-41.
158. Liu X, Min L, Duan H, et al. Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells. Med Oncol. 2015;32:364.
159. Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008;42:358-364.
160. Tsutsumi N, Kimura T, Arita K, et al. The structural basis for receptor recognition of human interleukin-18. Nat Commun. 2014;5:5340.
161. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95:6930-6935.
162. Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med. 1999;190:1541-1548.
163. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 1999;190:895-902.
164. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191:1069-1076.
165. Senn KA, McCoy KD, Maloy KJ, et al. T1-deficient and T1-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongylus brasiliensis. Eur J Immunol. 2000;30:1929-1938.
166. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107:18581-18586.
167. Zhiguang X, Wei C, Steven R, et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol Lett. 2010;131:159-165.
168. Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immuno. 2011;23:307-315.
169. Kim HY, Chang YJ, Subramanian S, et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol. 2012;129:216-227.
170. Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: In situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188: 3488-3495.
171. Bessa J, Meyer CA, de Vera Mudry MC, et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun. 2014;55:33-41.
172. Talabot-Ayer D, Martin P, Vesin C, et al. Severe neutrophil-dominated inflammation and enhanced myelopoiesis in IL-33-overexpressing CMV/IL33 mice. J Immunol. 2015;194:750-760.
173. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676-689.
174. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-304.
175. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol. 1998;161:4866-4874.
176. Peine M, Marek RM, Löhning M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol. 2016;37:321-333.
177. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188:1503-1513.
178. Sattler S, Ling GS, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 2014;50:107-122.
179. Zhu J, Xu Y, Zhu C, et al. IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis. Int Immunopharmacol. 2017;46:38-47.
180. Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA. 2009;106:13463-13468.
181. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564-568.
182. Baumann C, Bonilla WV, Fröhlich A, et al. T-bet-and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. 2015;112:4056-4061.
183. Sugita S, Hosaka Y, Okada K, et al. Transcription factor Hes1 modulates osteoarthritis development in cooperation with calcium/ calmodulin-dependent protein kinase 2. Proc Natl Acad Sci USA. 2015;112:3080-3085.
184. Zhao J, Wei J, Bowser RK, Traister RS, Fan MH, Zhao Y. Focal adhesion kinase-mediated activation of glycogen synthase kinase 3β regulates IL-33 receptor internalization and IL-33 signaling. J Immunol. 2015;194:795-802.
185. Zhao J, Wei J, Mialki RK, et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol. 2012;13:651-658.
186. Connolly DJ, O’Neill LA, McGettrick AF. The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J Biol Chem. 2013;288:5616-5623.
187. McGettrick AF, O’Neill LA. Localisation and trafficking of Toll-like receptors: An important mode of regulation. Curr Opin Immunol. 2010;22:20-27.
188. Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012;60:514-521.
189. Stroud RM, Wells JA. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE. 2004;231:re7.
190. Wjst M, Sargurupremraj M, Arnold M. Genome-wide association studies in asthma: What they really told us about pathogenesis. Curr Opin Allergy Clin Immunol. 2013;13:112-118.
191. Li R, Yang G, Yang R, Peng X, Li J. Interleukin-33 and receptor ST2 as indicators in patients with asthma: A meta-analysis. Int J Clin Exp Med. 2015;8:14935-14943.
192. Saluja R, Ketelaar ME, Hawro T, Church MK, Maurer M, Nawijn MC. The role of the IL-33/ IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol. 2015;63:80-85.
193. Smith D, Helgason H, Sulem P, et al. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet. 2017;13:e1006659.
194. Queiroz GA, Costa RS, Alcantara-Neves NM, et al. IL33 and IL1RL1 variants are associated with asthma and atopy in a Brazilian population. Int J Immunogenet. 2017;44:51-61.
195. Savenije OE, Kerkhof M, Reijmerink NE, et al. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol. 2011;127:750-756.
196. Savenije OE, Mahachie John JM, Grenell K, et al. Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. J Allergy Clin Immunol. 2014;134:170-177.
197. Griesenauer B, Paczesny S. The ST2/IL-33 Axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.
198. Hodzic Z, Schill EM, Bolock AM, Good M. IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine. 2017;100:1-10.
199. Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl). 2016;94:535-543.
200. Wasmer MH, Krebs P. The role of IL-33-dependent inflammation in the tumor microenvironment. Front Immunol. 2017;7:682.
201. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. 1999;31(10):1037-1051.
202. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23:16-43.
203. Rönnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004;61:2535-2548.
204. Hu ZQ, Zhao WH, Shimamura T. Regulation of mast cell development by inflammatory factors. Curr Med Chem. 2007;14:3044-3050.
205. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. Novel identified receptors on mast cells. Front Immunol. 2012 Aug;2(3):238.
206. Drube S, Heink S, Walter S, et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood. 2010;115:3899-3906.
207. Drube S, Schmitz F, Göpfert C, Weber F, Kamradt T. C-Kit controls IL-1β-induced effector functions in HMC-cells. Eur J Pharmacol. 2012;675:57-62.
208. https://www.ncbi.nlm.nih.gov/gene/8808
209. Vigne S, Palmer G, Lamacchia C, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118:5813-5823.
210. Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol. 2012;42:607-617.
211. Ramadas RA, Ewart SL, Medoff BD, LeVine AM. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol. 2011;44:134-145.
212. Ramadas RA, Ewart SL, Iwakura Y, Medoff BD, LeVine AM. IL-36α exerts pro-inflammatory effects in the lungs of mice. PLoS ONE. 2012;7:e45784.
213. Higgins J, Mutamba S, Mahida Y, Barrow P, Foster N. IL-36α induces maturation of Th1-inducing human MDDC and synergises with IFN-γ to induce high surface expression of CD14 and CD11c. Hum Immunol. 2015;76:245-253.
214. Magne D, Palmer G, Barton JL, et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther. 2006; 8:R80.
215. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620-628.
216. Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: What’s in a name? Arch Dermatol. 2012;148:381-384.
217. Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204:2603-2614.
218. Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/ IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89:432-437.
219. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000;12:59-63.
220. Kim SH, Eisenstein M, Reznikov L, et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA. 2000;97:1190-1195.
221. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J Immunol. 1998;161:3400-3407.
222. Debets R, Timans JC, Churakowa T, et al. IL-18 receptors, their role in ligand binding and function: Anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol. 2000;165:4950-4956.
223. Kato Z, Jee JG, Shikano H, et al. The structure and binding mode of interleukin-18. Nat Struct Biol. 2003;10:966-971.
224. Bossù P, Neumann D, Del Giudice E, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA. 2003;100:14181-14186.
225. Tedeschi A, Lorini M, Suli C, Asero R. Serum interleukin-18 in patients with chronic ordinary urticaria: Association with disease activity. Clin Exp Dermatol. 2007;32:568-570.
226. Migliorini P, Del Corso I, Tommasi C, Boraschi D. Free circulating interleukin-18 is elevated in Schnitzler syndrome: A new autoinflammatory disease? Eur Cytokine Netw. 2009;20:108-111.
227. Migliorini P, Anzilotti C, Pratesi F, et al. Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur Cytokine Netw. 2010;21:264-271.
228. Puxeddu I, Italiani P, Giungato P, et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine. 2013;61:741-743.
229. Italiani P, Carlesi C, Giungato P, et al. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflamm. 2014;11:94.
230. Capecchi R, Italiani P, Puxeddu I, et al. IL-1 family cytokines and receptors in IgG4-related disease. Cytokine. 2017. pii: S1043-4666(17)30227-2. (EPub ahead of print)
231. Boraschi D, Dinarello CA. IL-18 in autoimmunity. Eur Cytokine Netw. 2006;17:224-252.
232. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Sem Immunol. 2013;25:439-448.
233. https://www.ncbi.nlm.nih.gov/gene/8809
234. https://www.ncbi.nlm.nih.gov/gene/8807
235. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med. 2002;195:245-257.
236. Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, Werfel T. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol. 2003;171:6363-6371.
237. Xu D, Chan WL, et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med. 1998;188:1485-1492.
238. Neumann D, Martin MU. Interleukin-12 upregulates the IL-18Rβ chain in BALB/c thymocytes. J Interferon Cytokine Res. 2001;21:635-642.
239. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. IL-12 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol. 2002;169:3600-3605.
240. Hedl M, Zheng S, Abraham C. The IL18RAP region disease polymorphism decreases IL-18RAP/ IL-18R1/ IL-1R1 expression and signaling through innate receptor-initiated pathways. J Immunol. 2014;192:5924-5932.
241. Myhr CB, Hulme MA, Wasserfall CH, et al. The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFNγ production by PBMC. J Autoimmun. 2013;44:8-12.
242. Kim SH, Reznikov LL, Stuyt RJ, et al. Functional reconstitution and regulation of IL-18 activity by the IL-18R β chain. J Immunol. 2001;166:148-154.
243. Xu Y, Yue W, Shugart YY, et al. Potential involvement of the interleukin-18 pathway in schizophrenia. J Psychiatr Res. 2016;74:10-16.
244. Zhang J, Zheng L, Zhu D, et al. Polymorphisms in the interleukin 18 receptor 1 gene and tuberculosis susceptibility among Chinese. PLoS ONE. 2014;9:e110734.
245. Chung JH, Lee YC, Eun YG, et al. Single nucleotide polymorphism of interleukin-18 and interleukin-18 receptor and the risk of papillary thyroid cancer. Exp Clin Endocrinol Diabetes. 2015;123:598-603.
246. Koskinen LLE, Einarsdottir E, Dukes E, et al. Association study of the IL18RAP locus in three European populations with coeliac disease. Human Mol Genetics. 2009;18:1148-1155.
247. Wang YM, Li ZX, Tang FB, et al. Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol. 2016;37:2233-2242.
248. Hunt KA, Zhernakova A, Turner G, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nature Genet. 2008;40:395-402.
249. Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82:1202-1210.
250. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in Type 1 diabetes and celiac disease. New Engl J Med. 2008;359:2767-2777.
251. Wang X, Zhu YF, Li DM, et al. Polymorphisms of ST2-IL18R1-IL18RAP gene cluster: A new risk for autoimmune thyroid diseases. Int J Immunogenet. 2016;43:18-24.
252. Liu H, Irwanto A, Tian H, et al. Identification of IL18RAP/IL18R1 and IL12B as leprosy risk genes demonstrates shared pathogenesis between inflammation and infectious diseases. Am J Hum Genet. 2012;91:935-941.
253. Floros J, Londono D, Gordon D, et al. IL-18R1 and IL-18RAP SNPs may be associated with bronchopulmonary dysplasia in African-American infants. Pediatr Res. 2012;71:107-114.
254. Bodel P, Atkins E. Release of endogenous pyrogen by human monocytes. New Engl J Med. 1967;276:1002-1008.
255. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci. 2000;23:618-625.
256. Dinarello CA. IL-1: Discoveries, controversies and future directions. Eur J Immunol. 2010;40:599-606.
257. Andre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem. 2005;95:324-330.
258. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629-640.
259. Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE. Genomic organization of the interleukin-1 locus. Genomics. 2002;79:726-733.
260. Bossù P, Ciaramella A, Salani F, et al. Interleukin-18, from neuroinflammation to Alzheimer’s Disease. Curr Pharm Des. 2010;16:4213-4224.
261. Gutcher I, Urich E, Wolter K, Prinz M, Becher B. Interleukin 18-independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation. Nat Immunol. 2006;7:946-953.
262. Andre R, Wheeler RD, Collins PD, et al. Identification of a truncated IL-18R beta mRNA: A putative regulator of IL-18 expressed in rat brain. J Neuroimmunol. 2003;145:40-45.
263. Lu H-L, Yang C-Y, Chen H-C, Hung C-S, Chiang Y-C, Tang L-P. A novel alternatively spliced interleukin-1 receptor accessory protein mIL-1RAcP 687. Mol Immunol. 2008;45:1374-1384.
264. Smith DE, Lipsky BP, Russell C, et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity. 2009;30:817-831.
265. Nguyen L, Rothwell NJ, Pinteaux E, Boutin H. Contribution of interleukin-1 receptor accessory protein b to interleukin-1 actions in neuronal cells. Neurosignals. 2011;19:222-230.
266. Huang Y, Smith DE, Ibanez-Sandoval O, Sims JE, Fridman WJ. Neuron-specific effects of interleukin-1β are mediated by a novel isoform of the IL-1 receptor accessory protein. J Neurosci. 2011;31:18048-18059.
267. Gosselin D, Belalvance M-A, Rivest S. IL-1RAcPb signaling regulates adaptive mechanisms in neurons that promote their long-term serviva following excitotoxic insults. Frontiers Immunol. 2013;7:9.
268. Berglöf E, Andre R, Renshaw BR, et al. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol. 2003;139: 36-43.
269. Wang P, Meinhardt B, Andre R, et al. The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1β signalling responses. Cytokine. 2005;29:245-250.
270. Costelloe C, Watson M, Murphy A, et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem. 2008;105:1960-1969.
271. Fiszer D, Rozwadowska N, Rychlewski L, Kosicki W, Kurpisz M. Identification of IL-18RAP mRNA truncated splice variants in human testis and the other human tissues. Cytokine. 2007;39:178-183.
272. Watson MB, Costello DA, Carney DG, McQuillan K, Lynch MA. SIGIRR modulates the inflammatory response in the brain. Brain Behav Immun. 2010;24:985-995.
273. Costello DA, Watson MB, Cowley TR, et al. Interleukin-1α and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice. J Neurosci. 2011;2011(31):3871-3879.
274. Tomasoni R, Morini R, Lopez-Atalaya JP, et al. Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects. eLife. 2017;6:e21735.
275. Khan JA, Brint EK, O’Neill LAJ, Tong L. Crystal structure of the Toll/ Interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem. 2004;279:31664-31670.
276. Bahi N, Friocourt G, Carrie A, et al. IL1 receptor accessory protein like, a protein involved in X-linked mental retardation, interacts with Neuronal Calcium Sensor-1 and regulates exocytosis. Hum Mol Genet. 2003;12:1415-1425.
277. Yoshida T, Yasumura M, Uemura T, et al. IL-1 receptor accessory protein-like 1 associated with mental retardation and autism mediates synapse formation by trans-synaptic interaction with protein tyrosine phosphatase δ. J Neurosci. 2011;31:13485-13499.
278. Hayashi T, Yoshida T, Ra M, Taguchi R, Mishina M. IL1RAPL1 associated with mental retardation and autism regulates the formation and stabilization of glutamatergic synapses of cortical neurons through RhoA signaling pathway. PLoS ONE. 2013;8:e66254.
279. Piton A, Michaud JL, Peng H, et al. Mutations in the calcium-related gene IL1RAPL1 are associated with autism. Hum Mol Genet. 2008;17:3965-3974.
280. Melhem N, Middleton F, McFadden K, et al. Copy number variants for schizophrenia and related psychotic disorders in oceanic Palau: Risk and transmission in extended pedigrees. Biol Psychiatry. 2011;70:1115-1121.
281. Gao X, Xi G, Niu Y, et al. A study on the correlation between IL1RAPL1 and human cognitive ability. Neurosci Lett. 2008;438:163-167.
282. Aizawa H, Kobayashi M, Tanaka S, Fukai T, Okamoto H. Molecular characterization of the subnuclei in rat habenula. J Comp Neurol. 2012;520:4051-4066.
283. Sugama S, Cho BP, Baker H, Joh TH, Lucero J, Conti B. Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res. 2002;2002(958):1-9.
284. Yue JX, Meyers BC, Chen JQ, Tian D, Yang S. Tracing the origin and evolutionary history of plant nucleotide-binding site-leucine-rich repeat (NBS-LRR) genes. New Phytol. 2012;193:1049-1063.
285. Rana RR, Zhang M, Spear AM, Atkins HS, Byrne B. Bacterial TIR-containing proteins and host innate immune system evasion. Med Microbiol Immunol. 2013;202:1-10.
286. Nimma S, Ve T, Williams SJ, Kobe B. Towards the structure of the TIR-domain signalosome. Curr Opin Struct Biol. 2017;43:122-130.
287. Xu Y, Tao X, Shen B, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000;408:111-115.
288. Jang TH, Park HH. Crystal structure of TIR domain of TLR6 reveals novel dimeric interface of TIR-TIR interaction for toll-like receptor signaling pathway. J Mol Biol. 2014;426:3305-3313.
289. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarström M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem. 2008;283:11861-11865.
290. Valkov E, Stamp A, Dimaio F, et al. Crystal structure of Toll-like receptoradaptor MAL/TIRAP reveals the molecular basis for signal transduction and diseaseprotection. Proc Natl Acad Sci USA. 2011;108:14879-14884.
291. Enokizono Y, Kumeta H, Funami K, et al. Structures and interface mapping of the TIR domain-containing adaptor molecules involved in interferon signaling. Proc Natl Acad Sci USA. 2013;110:19908-19913.
292. Ohnishi H, Tochio H, Kato Z, et al. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA. 2009;106:10260-10265.
293. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure. 2011;19:447-459.
294. Bowie A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol. 2000;67:508-514.
295. Slack JL, Schooley K, Bonnert TP, et al. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J Biol Chem. 2000;275:4670-4678.
296. Kuno K, Okamoto S, Hirose K, Murakami S, Matsushima K. Structure and function of the intracellular portion of the mouse interleukin 1 receptor (type I). Determining the essential region for transducing signals to activate the interleukin 8 gene. J Biol Chem. 1993;268:13510-13518.
297. Radons J, Gabler S, Wesche H, Korherr C, Hofmeister R, Falk W. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem. 2002;277:16456-16463.
298. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta. 2002;1592:265-280.
299. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis. 2015;20:196-209.
300. Ve T, Williams SJ, Kobe B. Structure and function of Toll/interleukin-1 receptor/resistance protein (TIR) domains. Apoptosis. 2015;20:250-261.
301. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene. 1990;5:1095-1097.
302. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA. Dissection of the immediate early response of myeloid leukemia cells to terminal differentiation and growth inhibitory stimuli. Cell Growth Differ. 1990;1:637-645.
303. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem. 1998;273:12203-12209.
304. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis. 2003;35:555-562.
305. Ve T, Gay NJ, Mansell A, Kobe B, Kellie S. Adaptors in toll-like receptor signaling and their potential as therapeutic targets. Curr Drug Targets. 2012;13:1360-1374.
306. O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353-364.
307. Nishiya T, Kajita E, Horinouchi T, Nishimoto A, Miwa S. Distinct roles of TIR and non-TIR regions in the subcellular localization and signaling properties of MyD 88. FEBS Lett. 2007;581:3223-3229.
308. Janssens S, Burns K, Vercammen E, Tschopp J, Beyaert R. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB-and AP-1-dependent gene expression. FEBS Lett. 2003;548:103-107.
309. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci. 2002;27:474-482.
310. Li C, Zienkiewicz J, Hawiger J. Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem. 2005;280: 26152-26159.
311. Radons J, Dove S, Neumann D, et al. The interleukin 1 (IL-1) receptor accessory protein Toll/IL-1 receptor domain: Analysis of putative interaction sites in vitro mutagenesis and molecular modeling. J Biol Chem. 2003;278:49145-49153.
312. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature. 2010;465:885-890.
313. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14:546-558.
314. Vyncke L, Bovijn C, Pauwels E, et al. Reconstructing the TIR Side of the Myddosome: A paradigm for TIR-TIR interactions. Structure. 2016;24:437-447.
315. Chen CY, Liu HY, Hsueh YP. TLR3 downregulates expression of schizophrenia gene Disc1 via MYD88 to control neuronal morphology. EMBO Rep. 2017;18:169-183.
316. Fallon PG, Allen RL, Rich T. Primitive Toll signalling: Bugs, flies, worms and man. Trends Immunol. 2001;22:63-66.
317. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998;9:143-150.
318. Ferrao R, Wu H. Helical assembly in the death domain (DD) superfamily. Curr Opin Struct Biol. 2012;22:241-247.
319. Martin M, Böl GF, Eriksson A, Resch K, Brigelius-Flohé R. Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells. Eur J Immunol. 1994;24:1566-1571.
320. Croston GE, Cao Z, Goeddel DV. NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase activity. J Biol Chem. 1995;270:16514-16517.
321. Cao Z, Henzel WJ, Gao X. IRAK: A kinase associated with the interleukin-1 receptor. Science. 1996;271:1128-1131.
322. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem. 1999;274:19403-19410.
323. Li S, Strelow A, Fontana EJ, Wesche H. IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA. 2002;99:5567-5572.
324. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: Critical regulators of innate immune signalling. Biochem Pharmacol. 2010;80:1981-1991.
325. Kollewe C, Mackensen AC, Neumann D, et al. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem. 2004;279:5227-5236.
326. Neumann D, Kollewe C, Resch K, Martin MU. The death domain of IRAK-1: An oligomerization domain mediating interactions with MyD88, Tollip, IRAK-1, and IRAK-4. Biochem Biophys Res Commun. 2007;354:1089-1094.
327. Neumann D, Kollewe C, Pich A, Cao P, Resch K, Martin MU. Threonine 66 in the death domain of IRAK-1 is critical for interaction with signaling molecules but is not a target site for autophosphorylation. J Leukoc Biol. 2008;84:807-813.
328. Ferrao R, Zhou H, Shan Y, et al. IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly. Mol Cell. 2014;55:891-903.
329. Cushing L, Stochaj W, Siegel M, et al. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J Biol Chem. 2014;289:10865-10875.
330. Yamin TT, Miller DK. The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J Biol Chem. 1997;272:21540-21547.
331. Pauls E, Nanda SK, Smith H, Toth R, Arthur JSC, Cohen P. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J Immunol. 2013;191:2717-2730.
332. Vollmer S, Strickson S, Zhang T, et al. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. Biochem J. 2017;474:2027-2038.
333. Motshwene PG, Moncrieffe MC, Grossmann JG, et al. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem. 2009;284:25404-25411.
334. Dossang AC, Motshwene PG, Yang Y, et al. The N-terminal loop of IRAK-4 death domain regulates ordered assembly of the Myddosome signalling scaffold. Sci Rep. 2016;6:37267.
335. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol. 2000;2:346-351.
336. Moynagh PN. The roles of Pellino E3 ubiquitin ligases in immunity. Nat Rev Immunol. 2014;14:122-131.
337. Pacquelet S, Johnson JL, Ellis BA, et al. Cross-talk between IRAK-4 and the NADPH oxidase. Biochem J. 2007;403:451-461.
338. Ordureau A, Smith H, Windheim M, et al. The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK 1. Biochem J. 2008;409: 43-52.
339. Smith H, Peggie M, Campbell DG, Vandermoere F, Carrick E, Cohen P. Identification of the phosphorylation sites on the E3 ubiquitin ligase Pellino that are critical for activation by IRAK1 and IRAK4. Proc Natl Acad Sci USA. 2009;106:4584-4590.
340. Strickson S, Emmerich CH, Goh ETH, et al. Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling. Proc Natl Acad Sci USA. 2017;114:E3481-E3489.
341. Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 2002;418:443-447.
342. Yin Q, Lin SC, Lamothe B, et al. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol. 2009;16:658-666.
343. Baud V, Liu ZG, Bennett B, Suzuki N, Xia Y, Karin M. Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 1999;13:1297-1308.
344. Shim JH, Xiao C, Paschal AE, et al. TAK1, but not TAB 1 or TAB 2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005;19:2668-2681.
345. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 2005;6:1087-1095.
346. Hirata Y, Takahashi M, Morishita T, Noguchi T, Matsuzawa A. Post-translational modifications of the TAK1-TAB complex. Int J Mol Sci. 2017;18:pii: E205.
347. Rieser E, Cordier SM, Walczak H. Linear ubiquitination: A newly discovered regulator of cell signalling. Trends Biochem Sci. 2013;38:94-102.
348. Sasaki K, Iwai K. Roles of linear ubiquitinylation, a crucial regulator of NF-κB and cell death, in the immune system. Immunol Rev. 2015;266:175-189.
349. Cohen P, Strickson S. The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways. Cell Death Differ. 2017;24:1153-1159.
350. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-kB activity. Annu Rev Immunol. 2000;18:621-663.
351. O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. Sci STKE. 2000;2000:re1.
352. Cahill CM, Rogers JT. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/ IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem. 2008;283:25900-25912.
353. O’Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: Crucial receptors for inflammation and host defense. Immunol Today. 2000;21:206-209.
354. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3:cm1.
355. Yamada M, Nishizawa M, Natatake R, et al. Characterization of alternatively spliced isoforms of the type I interleukin-1 receptor on iNOS induction in rate hepatocytes. Nitric Oxide. 2007;17:98-105.
356. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV. Interleukin-1 receptor type 1 is a substrate for γ-secretase-dependent regulated intramembrane proteolysis. J Biol Chem. 2009;284:1394-1409.
357. Twomey C, Qian S, McCarthy V. TRAF6 promotes ubiquitination and regulated intramembrane proteolysis of IL-1R1. Biochem Biophys Res Commun. 2009;381:418-423.
358. Orlando S, Sironi M, Bianchi G, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem. 1997;272:31764-31769.
359. Lorenzen I, Lokau J, Dusterhoft S, et al. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett. 2012;586:1093-1100.
360. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J Biol Chem. 2000;275:14608-14614.
361. Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol. 2003;171:6814-6819.
362. Kuhn P-H, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by α-β-, and γ-secretase. J Biol Chem. 2007;282:11982-11995.
363. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 2011;32:110-116.
364. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1 β and inflammatory disease. J Biol Chem. 1990;265:6318-6322.
365. Smith DE, Hanna R, Friend D, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003;18:87-96.
366. Liu C, Hart RP, Liu X-J, Clevenger W, Maki R, De Souza EB. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem. 1996;271:20965-20972.
367. Smith GL, Chan YS. Two vaccinia proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol. 1991;72:511-518.
368. Alcami A, Smith GL. A soluble receptor for interleukin-1β encoded by vaccinia virus: A novel mechanism of vurus modulation of the host response to infection. Cell. 1992;71:153-167.
369. Spriggs MK, Hruby DE, Maliszewski CR, et al. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell. 1992;71:145-152.
370. Farré D, Martinez-Vicente P, Engel P, Angulo A. Immunoglobulin superfamily members encoded by viruses and their multiple roleds in immune evasion. Eur J Immunol. 2017;47:780-796.
371. Smeets RL, Joosten LAB, Arntz OJ, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthr Rheum. 2005;52:2202-2211.
372. Smeets RL, van de Loo FA, Joosten LA, et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum. 2003;48:2949-2958.
373. Kuroiwa K, Li H, Tago K, et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma. 2000;19:151-159.
374. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-281.
375. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284:1104-1108.
376. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124:1206-1214.
377. Bhardwaj A, Januzzi JL Jr. ST2: A novel biomarker for heart failure. Expert Rev Mol Diagn. 2010;10:459-464.
378. Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol. 2013;6:311-318.
379. Bayes-Genis A, Januzzi JL, eds. The international ST2 consensus panel. Am J Cardiol. 2015;115:1B-80B.
380. Alboni S, Cervia D, Ross B, et al. Mapping of the full length and the truncated interleukin-18 receptor alpha in the mouse brain. J Neuroimmunol. 2009;214:43-54.
381. Booker CS, Grattan DR. Identification of a truncated splice variant of IL-18 receptor alpha in the human and rat, with evidence of wider evolutionary conservation. PeerJ. 2014;2:e560.
382. Veenbergen S, Smeets RL, Bennink MB, et al. The natural soluble form of IL-18 receptor β exacerbates collagen-induced arthritis via modulation of T-cell immune responses. Ann Rheum Dis. 2010;69:276-283.
383. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011;22:127-147.
384. Watanabe M, Goto N, Watanabe Y, et al. Evolution of interleukin-18 binding proteins and interleukin-1 receptor, type II proteins. Int J Mol Med. 2005;15:561-566.
385. Xiang Y, Moss B. IL-18 binding and inhibition of interferon γ induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA. 1999;96:11537-11542.
386. Born TL, Morrison LA, Esteban DJ, et al. A poxvirus protein that binds to and inactivates IL-18 and inhibits NK cell response. J Immunol. 2000;164:3246-3254.
387. Calderara S, Xiang Y, Moss B. Orthopoxvirus IL-18 binding proteins: Affinities and antagonistic activities. Virology. 2001;279:22-26.
388. Reading PC, Smith GL. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing γ interferon production and natiral killer and T cell activity. J Virol. 2003;77:9960-9968.
389. Xiang Y, Moss B. Molluscum contagiosum virus interleukin-18 (IL-18) binding protein is secreted as a full-length form that binds cell surface glycosaminoglycans through the C-terminal tail and a furin-cleaved form with only the IL-18 binding domain. J Virol. 2003;77:2323-2630.
390. Esteban DJ, Nuara AA, Buller RML. Interleukin-18 and glycosaminoglycan binding by a protein encoded by Variola virus. J Gen Virol. 2004;85:1291-1299.
391. Krumm B, Meng X, Li Y, Xiang Y, Deng J. Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. Proc Natl Acad Sci USA. 2008;105:20711-20715.
392. Paulukat J, Bosmann M, Nold M, et al. Expression and release of IL-18 binding protein in response to IFN-γ. J Immunol. 2001;167:7038-7043.
393. Bresnihan B, Roux-Lombard P, Murphy E, Kane D, FitzGerald O, Dayer JM. Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann Rheum Dis. 2002;61:726-729.
394. Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14:334-342.
395. Vigers GPA, Caffes P, Evans RJ, Thompson RC, Eisenberg SP, Brandhuber BJ. X-ray structure of interleukin-1 receptor antagonista t 2.0-Å resolution. J Biol Chem. 1994;269:12874-12879.
396. Arend WP, Guthridge CJ. Biological role of interleukin-1 receptor antagonist isoforms. Ann Rheum Dis. 2000;59:i60-i64.
397. Dinarello CA, van der Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Sem Immunol. 2013;25:469-484.
398. Dinarello CA, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol. 2010;11:973.
399. Dinarello CA, Nold-Petry C, Fujita M, Li S, Kim S, Bufler P. Suppression of innate inflammation and immunity by interleukin family member Interleukin-37. Eur J Immunol. 2016;46:1067-1081.
400. Pan G, Risser P, Mao W, et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 2001;13:1-7.
401. Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol. 2008;180:5477-5482.
402. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014-1022.
403. Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16:354-365.
404. Ellisdon AM, Nold-Petry CA, D’Andrea L, et al. Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Sci Immunol. 2017;2:eaaj1548.
405. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res. 2001;21:899-904.
406. Takenaka S, Kaieda S, Kawayama T, et al. IL38: A new factor in rheumatoid arthritis. Biochem Biophys Res Commun. 2015;4:386-391.
407. Boutet M-A, Najm A, Bart G, et al. IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro. Ann Rheum Dis. 2017;76:1304-1312.
408. Peters VA, Joesting JJ, Freund GG. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain Behav Immun. 2013;32:1-8.
409. Malinowsky D, Lundkvist J, Laye S, Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett. 1998;429:299-302.
410. Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-α stimulates expression of TNF-α converting enzyme in endothelial cells. Eur J Biochem. 2004;271:2808-2820.
411. Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor α-induced increases in tumor necrosis factor-α converting enzyme/ADAM17 expression by synovial cells. J Biol Chem. 2007;282:33714-33724.
412. Martin P, Palmer G, Vigne S, et al. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leuk Biol. 2013;94:791-802.
413. Uchikawa S, Yoda M, Tohmonda T, et al. ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine. 2015;71:238-245.
414. Shimizu K, Nakajima A, Sudo K, et al. IL-1 Receptor Type 2 suppresses collagen-induced arthritis by inhibiting IL-1 signal on macrophages. J Immunol. 2015;194:3156-3168.
415. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MCH. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity. 2013;38:285-295.
416. Weihofen A, Martoglio B. Intramembrane-cleaving proteases: Controlled liberation of proteins and bioactive peptides. Trends Cell Biol. 2003;13:71-78.
417. Kopan R, Ilagan MX. Gamma-secretase: Proteasome of the membrane? Nat Rev Mol Cell Biol. 2004;5:499-504.
418. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001;166:6633-6639.
419. Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol. 2004;5:373-379.
420. Liu J, Buckley JM, Redmond HP, Wang JH. ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance. J Immunol. 2010;184:5802-5808.
421. Basith S, Manavalan B, Govindaraj RG, Choi S. In silico approach to inhibition of signaling pathways of Toll-Like Receptors 2 and 4 by ST2L. PLoS ONE. 2011;6:e23989.
422. Rebl A, Rebl H, Köbis JM, Goldammer T, Seyfert H-M. ST2 from rainbow trout quenches TLR signalling, localises at the nuclear membrane and allows the nuclear translocation of MYD88. Dev Comp Immunol. 2017;67:139-152.
423. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA. 2004;101:3522-3526.
424. Bulek K, Swaidani S, Qin J, et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol. 2009;182:2601-2609.
425. Molgora M, Barajon I, Mantovani A, Garlanda C. Regulatory role of IL-1R8 in immunity and disease. Front Immunol. 2016;7:149.
426. Molgora M, Bonavita E, Ponzetta A, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature. 2017;551:110-114.
427. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998;8: 383-390.
428. O’Neill LA. The Toll/interleukin-1 receptor domain: A molecular switch for inflammation and host defence. Biochem Soc Trans. 2000;28:557-563.
429. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447-491.
430. O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10-18.
431. Luo C, Zheng L. Independent evolution of Toll and related genes in insects and mammals. Immunogenetics. 2000;51:92-98.
432. Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. 2003;24:19-24.
433. Ausubel FM. Are innate immune signaling pathways in plants and animals conserved? Nat Immunol. 2005;6:973-979.
434. Kimbrell DA, Beutler B. The evolution and genetics of innate immunity. Nat Rev Genet. 2001;2:256-267.
435. Meyers BC, Kozik A, Griego A, Kuang H, Michelmore RW. Genome-wide analysis of NBS-LRR-encoding genes in Arabidopsis. Plant Cell. 2003;15:809-834.
436. Gerdol M, Venier P, Edomi P, Pallavicini A. Diversity and evolution of TIR-domain-containing proteins in bivalves and Metazoa: New insights from comparative genomics. Dev Comp Immunol. 2017;70:145-164.
437. Beck G, Ellis TW, Truong N. Characterization of an IL-1 receptor from Asterias forbesi coelomocytes. Cell Immunol. 2000;203:66-73.
438. Gauthier ME, Du Pasquier L, Degnan BM. The genome of the sponge Amphimedon queenslandica provides new perspectives into the origin of Toll-like and interleukin 1 receptor pathways. Evol Dev. 2010;12:519-533.
439. Hibino T, Loza-Coll M, Messier C, et al. The immune gene repertoire encoded in the purple sea urchin genome. Dev Biol. 2006;300:349-365.
440. Huang S, Yuan S, Guo L, et al. Genomic analysis of the immune gene repertoire of amphioxus reveals extraordinary innate complexity and diversity. Genome Res. 2008;18:1112-1126.
441. Gerber S, Cadet P, Sheenan M, Stefano GB, Mantione KJ. Vertebrate interleukins originated in invertebrates? Invert Surv J. 2007;4:95-100.
442. Cateni C, Paulesu L, Bigliardi E, Hamlett WC. The interleukin 1 (IL-1) system in the uteroplacental complex of a cartilaginous fish, the smoothhound shark, Mustelus canis. Reprod Biol Endocrinol. 2003;1:25.
443. Subramaniam S, Stansberg C, Olsen L, Zou J, Secombes CJ, Cunningham C. Cloning of a Salmo salar interleukin-1 receptor-like cDNA. Dev Comp Immunol. 2002;26:415-431.
444. Zou J, Grabowski PS, Cunningham C, Secombes CJ. Molecular cloning of interleukin 1beta from rainbow trout Oncorhynchus mykiss reveals no evidence of an ice cut site. Cytokine. 1999;11:552-560.
445. Sangrador-Vegas A, Martin SA, O’Dea PG, Smith TJ. Cloning and characterization of the rainbow trout (Oncorhynchus mykiss) type II interleukin-1 receptor cDNA. Eur J Biochem. 2000;267:7031-7037.
446. Huising MO, Stet RJM, Savelkoul HFJ, Verburg-van Kemenade BML. The molecular evolution of the interleukin-1 family of cytokines; IL-18 in teleost fish. Dev Comp Immunol. 2004;28:395-413.
447. Stansberg C, Subramaniam S, Collet B, Secombes CJ, Cunningham C. Cloning of the Atlantic salmon (Salmo salar) IL-1 receptor associated protein. Fish Shellfish Immunol. 2005;19:53-65.
448. Stansberg C, Subramaniam S, Olsen L, Secombes CJ, Cunningham C. Cloning and characterisation of a putative ST2L homologue from Atlantic salmon (Salmo salar). Fish Shellfish Immunol. 2003;15:211-224.
449. Jantra S, Bigliardi E, Brizzi R, Ietta F, Bechi N, Paulesu L. Interleukin 1 in oviductal tissue of viviparous, oviparous, and ovuliparous species of amphibians. Biol Reproduct. 2007;76:1009-1015.
450. Paulesu L, Romagnoli R, Marchetti M, et al. Cytokines in the viviparous reproduction of squamate reptiles: Interleukin-1α (IL-1α) and IL-1β in placental structures of a skink. Placenta. 1995;16:193-205.
451. Guida S, Heguy A, Melli M. The chicken IL-1 receptor: Differential evolution of the cytoplasmic and extracellular domains. Gene. 1992;111:239-243.
452. Beschin A, Bilej M, Torreele E, De Baetselier P. On the existence of cytokines in invertebrates. Cell Mol Life Sci. 2001;58:801-814.
453. Zhang Q, Zmasek CM, Godzik A. Domain architecture evolution of pattern-recognition receptors. Immunogenetics. 2010;62:263-272.
454. Zhang SM, Adema CM, Kepler TB, Loker ES. Diversification of Ig superfamily genes in an invertebrate. Science. 2004;305:251-254.
455. Murzin AG, Lesk AM, Chothia C. Beta-trefoil fold patterns of structure and sequence in the Kunitz inhibitors interleukins-1β and 1α and fibroblast growth factors. J Mol Biol. 1992;223:531-543.
456. Feng J, Li M, Huang Y, Xiao Y. Symmetric key structural residues in symemtric proteins beta-trefoil fold. PLoSONE. 2010;5:e14138.
457. Sweet RM, Wright HT, Janin J, Chothia CH, Blow DM. Crystal structure of the complex of porcine trypsin with soybean trypsin inhibitor (Kunitz) at 2.6-Å resolution. Biochemistry. 1974;13:4212-4228.
458. McLachlan AD. Three-fold structural pattern in the soybean trypsin inhibitor (Kunitz). J Mol Biol. 1979;133:557-563.
459. Drenth J, Jansonius JN, Koekoek R, Wolthers BG. The structure of papain. Adv Prot Chem. 1971;25:79-115.
460. Vainshtein BK, Melik-Adamyan WR, Barynin VV, et al. Three-dimensional structure of catalase from Penicillium vitale at 2.0 Å resolution. J Mol Biol. 1986;188:49-61.
461. Habazettl J, Gondol D, Wiltscheck R, Otlewski J, Schleicher M, Holak TA. Structure of hisactophilin is similar to interleukin-1β and fibroblast growth factor. Nature. 1992;359:855-858.